EUVIMEDEUVIMED entdecken
Open Access

Cerebrovascular Dysfunction in Alzheimer’s Disease and Transgenic Rodent Models

Xing Fang, Fan Fan, Jane J Border, Richard J Roman

Journal of Experimental Neurology · 2024

DOI: 10.33696/neurol.5.087 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Experimental Neurology, 2024. Verfasst von Xing Fang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, MS 39216, USA. Die Arbeit wurde bisher 16-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NHLBI NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s Disease (AD) and Alzheimer’s Disease-Related Dementia (ADRD) are the primary causes of dementia that has a devastating effect on the quality of life and is a tremendous economic burden on the healthcare system. The accumulation of extracellular beta-amyloid (Aβ) plaques and intracellular hyperphosphorylated tau-containing neurofibrillary tangles (NFTs) in the brain are the hallmarks of AD. They are also thought to be the underlying cause of inflammation, neurodegeneration, brain atrophy, and cognitive impairments that accompany AD. The discovery of APP, PS1, and PS2 mutations that increase Aβ production in families with early onset familial AD led to the development of numerous transgenic rodent models of AD. These models have provided new insight into the role of Aβ in AD; however, they do not fully replicate AD pathology in patients. Familial AD patients with mutations that elevate the production of Aβ represent only a small fraction of dementia patients. In contrast, those with late-onset sporadic AD constitute the majority of cases. This observation, along with the failure of previous clinical trials targeting Aβ or Tau and the modest success of recent trials using Aβ monoclonal antibodies, has led to a reappraisal of the view that Aβ accumulation is the sole factor in the pathogenesis of AD. More recent studies have established that cerebral vascular dysfunction is one of the earliest changes seen in AD, and 67% of the candidate genes linked to AD are expressed in the cerebral vasculature. Thus, there is an increasing appreciation of the vascular contribution to AD, and the National Institute on Aging (NIA) and the Alzheimer’s Disease Foundation recently prioritized it as a focused research area. This review summarizes the strengths and limitations of the most commonly used transgenic AD animal models and current views about the contribution of Aβ accumulation versus cerebrovascular dysfunction in the pathogenesis of AD.

Schlagwörter

Stichwörter der Autor:innen

AD animal modelsAlzheimer’s diseaseBeta-amyloidBrain hypoperfusionCerebrovascular dysfunctionNeurovascular couplingTau

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, MS 39216, USA.
  • Department of Physiology, Augusta University, Augusta, GA 30912, USA.

Förderung

  • NIA NIH HHS
  • NHLBI NIH HHS
  • National Institutes of Health
  • American Heart Association

Zitieren

APA

Fang, X., Fan, F., Border, J. J., & Roman, R. J. (2024). Cerebrovascular Dysfunction in Alzheimer’s Disease and Transgenic Rodent Models. Journal of Experimental Neurology. https://doi.org/10.33696/neurol.5.087

Vancouver

Fang X, Fan F, Border JJ, Roman RJ. Cerebrovascular Dysfunction in Alzheimer’s Disease and Transgenic Rodent Models. Journal of Experimental Neurology. 2024. doi:10.33696/neurol.5.087

BibTeX
@article{Fang2024,
  author = {Fang, Xing and Fan, Fan and Border, Jane J and Roman, Richard J},
  title = {Cerebrovascular Dysfunction in Alzheimer’s Disease and Transgenic Rodent Models},
  journal = {Journal of Experimental Neurology},
  year = {2024},
  doi = {10.33696/neurol.5.087}
}
Kostenlos starten →